Featured Publications
Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial
Dwyer JB, Landeros-Weisenberger A, Johnson JA, Londono Tobon A, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. American Journal Of Psychiatry 2021, 178: 352-362. PMID: 33653121, DOI: 10.1176/appi.ajp.2020.20010018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntidepressive AgentsCross-Over StudiesDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDouble-Blind MethodFemaleHumansHypnotics and SedativesInfusions, IntravenousKetamineMaleMidazolamProof of Concept StudyTreatment OutcomeConceptsTreatment-resistant depressionDepression Rating ScaleIntravenous ketamineClinical trialsAdolescent treatment-resistant depressionAdult treatment-resistant depressionPlacebo-controlled clinical trialSignificant short-term efficacySerious adverse eventsPrimary outcome measureSingle intravenous infusionChildren's Depression Rating ScaleCrossover clinical trialShort-term efficacyMajor depressive disorderSingle ketamine infusionSymptoms 24 hoursLater time pointsKetamine’s safetyAdverse eventsAntidepressant medicationKetamine infusionPediatric populationSignificant morbidityIntravenous infusionAnnual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer JB, Stringaris A, Brent DA, Bloch MH. Annual Research Review: Defining and treating pediatric treatment‐resistant depression. Journal Of Child Psychology And Psychiatry 2020, 61: 312-332. PMID: 32020643, PMCID: PMC8314167, DOI: 10.1111/jcpp.13202.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntidepressive AgentsCombined Modality TherapyDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDrug Therapy, CombinationHumansPsychotherapySelective Serotonin Reuptake InhibitorsConceptsTreatment-resistant depressionMajor depressive disorderAdolescent treatment-resistant depressionRisk factorsAdolescent major depressive disorderPsychotherapy treatment trialSecond-line treatmentSignificant risk factorsPediatric clinical trialsSecond leading causeSignificant health problemEvidence-based psychotherapiesCent of adolescentsMedication switchAdequate medicationSubstantial morbiditySymptom improvementInterventional treatmentMedication augmentationTreatment trialsCare treatmentClinical trialsDepressive disorderDiagnostic difficultiesLeading cause
2023
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression
Lineham A, Avila-Quintero V, Bloch M, Dwyer J. The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression. Journal Of Child And Adolescent Psychopharmacology 2023, 33: 20-26. PMID: 36799961, DOI: 10.1089/cap.2022.0086.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntidepressive AgentsChildDepressionDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDouble-Blind MethodHumansKetamineMidazolamTreatment OutcomeConceptsTreatment-resistant depressionDepression symptom improvementAcute dissociative symptomsAntidepressant responseSymptom improvementRapid-acting antidepressant agentsSignificant associationDissociative symptomsLikelihood of responseDissociation symptomsMagnitude of associationDissociative effectsKetamine groupPediatric patientsCrossover trialPediatric populationAntidepressant agentsKetamine responseAdolescent patientsAdult studiesDepression responseSecondary data analysisTreatment responseDepressive symptomsTrial design